Previous 10 | Next 10 |
Amarin Corp. ( NASDAQ: AMRN ) shares are up ~8% in Tuesday afternoon trading after Sarissa Capital Management, the company's largest shareholder, had seven of its backed individuals elected to the board and current chairman Per Wold-Olsen tossed. The new board will have 15 members...
Sarissa honored to have received 100 million more votes than Amarin board Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board...
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023...
Amarin ( NASDAQ: AMRN ) is licensing exclusive rights to Vazkepa to CSL Seqirus to secure pricing and reimbursement, and sell the heart drug in Australia and New Zealand. Under the agreement, Amarin will receive an upfront payment and be eligible for event-related miles...
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive...
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today issued the following statement in response to Sarissa’s latest misstatements regarding the Company’s managemen...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data evaluating the role of VASCEPA ® /VAZKEPA ® (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk pati...
Sarissa believes Amarin board acted in bad faith by making these equity grants while refusing to disclose proxy contest results and will hold each director personally accountable Sarissa urges Amarin CEO Karim Mikhail to repudiate his undeserved equity grants and re-issue them to hard wor...
Summary Amarin and Sarissa are engaged in a bitter proxy war. Amarin has problems, but Sarissa doesn't have clear solutions. Amarin has given considerable proof of how its new management performed in the last few quarters. Amarin ( AMRN ) and Sarissa are engaged in a m...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference. Cowen Annual Hea...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...